Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

154 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-05-09

Study Completion Date

2012-06-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To estimate the effect of KRAS mutation status (Wild-type versus Mutant) on objective response rate and other measures of efficacy for patients treated with panitumumab in combination with a chemotherapy regimen of irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line therapy for metastatic colorectal cancer (mCRC).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment

NCT00411450

Colon Cancer Colorectal Cancer Rectal Cancer +4 more

COMPLETED PHASE2

A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy

NCT01144195

Metastatic Colorectal Cancer

UNKNOWN PHASE2

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

NCT01226719

Colorectal Cancer

COMPLETED PHASE2

FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status

NCT03142516

Colorectal Neoplasms Colorectal Carcinoma Colorectal Cancer Metastatic +1 more

COMPLETED PHASE2

FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer

NCT02508077

Recurrent Colorectal Carcinoma Stage IVA Colorectal Cancer Stage IVB Colorectal Cancer

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Panitumumab plus FOLFIRI

Participants received 6 mg/kg panitumumab intravenously (IV) once every 14 days in combination with FOLFIRI chemotherapy regimen consisting of irinotecan, infusional 5-fluorouracil, and leucovorin, until diagnosed with radiographic disease progression.

Group Type EXPERIMENTAL

Panitumumab

Intervention Type DRUG

Administered by intravenous infusion

FOLFIRI

Intervention Type DRUG

FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m², leucovorin 400 mg/m², 5-fluorouracil bolus 400 mg/m², 5-fluorouracil infusion 2400 mg/m².

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Panitumumab

Administered by intravenous infusion

Intervention Type DRUG

FOLFIRI

FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m², leucovorin 400 mg/m², 5-fluorouracil bolus 400 mg/m², 5-fluorouracil infusion 2400 mg/m².

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Vectibix

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with histologically- or cytologically-confirmed metastatic adenocarcinoma of the colon and/or rectum.
* Measurable disease according to modified RECIST guidelines.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
* Paraffin-embedded tissue or unstained tumour slides from primary or metastatic tumour available for central lab analysis.
* Adequate haematologic, renal, hepatic and metabolic function.

Exclusion Criteria

* Central nervous system metastases.
* Prior systemic therapy for the treatment of metastatic colorectal carcinoma with the exception of adjuvant fluoropyrimidine-based chemotherapy given at least six months prior to initiating study treatment.
* Prior anti-epidermal growth factor receptor (EGFr) antibody therapy (e.g. cetuximab) or treatment with small molecule EGFr tyrosine kinase inhibitors (e.g. erlotinib).
* Prior radiotherapy within 14 days prior to screening, and for which all signs of early radiological toxicity have not abated.
* Significant cardiovascular disease including unstable angina or myocardial infarction within six months before initiating study treatment or a history of ventricular arrhythmia.
* History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline chest computed tomography (CT scan.
* Active inflammatory bowel disease or other bowel disease causing chronic diarrhoea (defined as \> 4 loose stools per day).
* History of Gilbert's syndrome or dihydropyrimidine deficiency.
* Known positive test for human immunodeficiency virus infection, hepatitis C virus, chronic active hepatitis B infection.
* Any investigational agent within 30 days before initiation of study treatment.
* Must not have had a major surgical procedure within 28 days prior to initiation of study treatment.
* Subject who is pregnant or breast-feeding.
* Woman or man of childbearing potential not consenting to use adequate contraceptive precautions during the course of the study and for six months after the last study drug administration for women, and one month for men.

* Other protocol specified criteria and specific details may apply.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No